

31 October 2011

TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and the 2009/10 Invitation to Tender, dated 4 December 2009.

As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers.

Some of the pharmaceuticals that will be delisted when the period of Sole Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12th of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp.

Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

2010/11 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2014

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Ethinylestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tablets; 84 tablets, blister pack	\$6.62	\$2.45	Ava 30 ED (Arrow)	1 April 2012	1 June 2012	1 September 2012	Levlen ED Microgynon 30 ED (Bayer) Monofeme Nordette 28 (Pfizer)
Rizatriptan	Orodispersible tab 10 mg; 30 tablets, blister pack	\$25.32 (per 3 tablets)	\$18.00 (per 30 tablets)	Rizamelt (Mylan)	1 March 2012	1 May 2012	1 August 2012	Maxalt Melt (MSD)
Ursodeoxycholic acid	Cap 250 mg; 100 capsules, blister pack	\$179.00	\$71.50	Ursosan (ABM)	1 March 2012	1 May 2012	1 August 2012	Actigall (Novartis)

2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Testosterone cypionate	Inj long-acting 100 mg per ml, 10 ml; 1 vial	\$61.41	\$76.50	Depo- Testosterone (Pfizer)	1 December 2011	1 March 2012

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Rizatriptan	Orodispersible tab 10 mg; 30 tablets, blister pack	\$25.32 (per 3 tablets)	\$18.00 (per 30 tablets)	Rizamelt (Mylan)	1%	1 March 2012	1 May 2012	Maxalt Melt (MSD)
Ursodeoxycholic acid	Cap 250 mg; 100 capsules, blister pack	\$179.00	\$71.50	Ursosan (ABM)	1%	1 March 2012	1 May 2012	Actigall (Novartis)

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Testosterone cypionate	Inj long-acting 100 mg per ml, 10 ml; 1 vial	\$61.41	\$76.50	Depo-Testosterone (Pfizer)	1%	1 December 2011	1 February 2012

2009/10 Tender – Sole Supply Status or Hospital Supply Status applies until 30 June 2013

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and price	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Tetrabenazine	Tab 25 mg; 112 tablets, bottle	\$243.00	\$178.00	Motetis (Douglas)	1 March 2012	1 May 2012	1 August 2012	Xenazine 25 (AFT)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Tetrabenazine	Tab 25 mg; 112 tablets, bottle	\$178.00	Motetis (Douglas)	1%	1 March 2012	1 May 2012

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name	Line Item
Ethinylloestradiol with levonorgestrel	Tab 30 mcg with levonorgestrel 150 mcg

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.